ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 039,81
0,42%
Dow Jones
38 914,67
0,28%
DAX
18 644,04
0,40%
Brent Oil
79,055
0,63%
Bitcoin
71 108,91
0,04%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
04/06/202422h05Business WireTeva to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/202420h25Business WireNew Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/06/202420h20Business WireTeva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
30/05/202400h38Business WireTeva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)NYSE:TEVATeva Pharmaceutical Industries Ltd
21/05/202402h25Business WireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/202414h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/202414h30Edgar (US Regulatory)Form 8-K - Current reportNYSE:TEVATeva Pharmaceutical Industries Ltd
15/05/202414h15Business WireTeva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global OperationsNYSE:TEVATeva Pharmaceutical Industries Ltd
09/05/202413h53IH Market NewsBain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More NewsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/05/202413h00Business WireTeva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial OutlookNYSE:TEVATeva Pharmaceutical Industries Ltd
08/05/202412h30Business WireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/202400h30Business WireTeva to Present at the 2024 Bank of America Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
02/05/202414h30Business WireTeva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious TargetsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/04/202410h00GlobeNewswire Inc.U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
16/04/202423h43Business WireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
16/04/202414h00Business WireTeva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) TabletsNYSE:TEVATeva Pharmaceutical Industries Ltd
11/04/202414h30Business WireTeva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in ChinaNYSE:TEVATeva Pharmaceutical Industries Ltd
09/04/202422h30Business WireTeva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
06/04/202419h00Business WireNew Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024NYSE:TEVATeva Pharmaceutical Industries Ltd
04/04/202414h30Business WireTeva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar CandidateNYSE:TEVATeva Pharmaceutical Industries Ltd
01/04/202414h30Business WireClinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding AgreementNYSE:TEVATeva Pharmaceutical Industries Ltd
05/03/202422h43Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:TEVATeva Pharmaceutical Industries Ltd
26/02/202413h00Business WireTeva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in ChinaNYSE:TEVATeva Pharmaceutical Industries Ltd
24/02/202402h15GlobeNewswire Inc.Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NYSE:TEVATeva Pharmaceutical Industries Ltd
24/02/202402h15Business WireAlvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®NYSE:TEVATeva Pharmaceutical Industries Ltd
20/02/202414h30Business WireTeva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
13/02/202415h05IH Market NewsHotter-Than-Expected Inflation Data Likely To Weigh On Wall StreetNYSE:TEVATeva Pharmaceutical Industries Ltd
12/02/202423h03IH Market NewsDow Reaches New Record Closing High But Nasdaq, S&P 500 Give Back GroundNYSE:TEVATeva Pharmaceutical Industries Ltd
12/02/202415h13IH Market NewsTeva Pharmaceutical, Urban Outfitters UpgradedNYSE:TEVATeva Pharmaceutical Industries Ltd
31/01/202413h00Business WireTeva Reports Growth in Fourth Quarter and Full Year 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

TSXV
CCCA.P
Cedarmont Capital
EU
DEUAH
Departement de L Eure 0....
EU
VDPBT
Ville de Paris 0.464% un...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés